RT Journal Article
SR Electronic
T1 <em>O</em>
<sup>6</sup>-Benzylguanine Enhances the In Vitro Immunotoxic Activity of Temozolomide on Natural or Antigen-Dependent Immunity
JF Journal of Pharmacology and Experimental Therapeutics
JO J Pharmacol Exp Ther
FD American Society for Pharmacology and Experimental Therapeutics
SP 1292
OP 1300
VO 291
IS 3
A1 Ester Alvino
A1 Rita Pepponi
A1 Elena Pagani
A1 Pedro Miguel Lacal
A1 Corrado Nunziata
A1 Enzo Bonmassar
A1 Stefania D'Atri
YR 1999
UL http://jpet.aspetjournals.org/content/291/3/1292.abstract
AB Temozolomide (TMZ) is a new cytotoxic triazene compound of clinical interest that is able to generate methyl adducts at theO6-guanine of DNA, which can be repaired byO6-alkylguanine-DNA alkyltransferase (OGAT). It was previously found that triazene compounds are highly immunosuppressive in mice. In the present study, we investigate whether TMZ could affect immune functions of human competent cells and whether methylation of O6-guanine could be involved in the immunosuppressive activity of the drug. Mononuclear cells (MNCs) obtained from peripheral blood of healthy donors were tested for OGAT activity and treated with TMZ alone or combined with the OGAT inhibitorO6-benzylguanine. Control or drug-treated MNCs were then assayed for natural killer activity and for the ability to proliferate and to generate cytotoxic effector cells in response to interleukin-2 or allogeneic MT-2 tumor cells. The results show that TMZ inhibited both proliferation and induction of lytic activity in response to interleukin-2 or allogeneic MT-2 cells. Moreover, an inverse correlation was found between the OGAT activity of MNCs and their sensitivity to TMZ. The involvement ofO6-guanine methylation in the immunosuppressive effects of TMZ was further confirmed by the finding that O6-benzylguanine increased the activity of the drug. On the other hand, the natural killer activity of MNCs was only moderately affected by TMZ, and no relationship was observed between OGAT levels and sensitivity to the drug. These data suggest that in patients with tumors who are undergoing TMZ treatment, the drug may impair immune responses involving cell proliferation, depending on OGAT levels of MNCs, and thatO6-benzylguanine may potentiate this activity. The American Society for Pharmacology and Experimental Therapeutics